Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRISOTE benralizumab add-on study in uncontrolled eosinophilic asthma
2024-515162-13-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic asthma (EA) comparing Benralizumab add-on with Placebo add-on control (2 arms). Primary endpoint: Annualized asthma exacerbation rate. Started Apr 2025; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2024-515162-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515162-13-00.